BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27122302)

  • 1. New Insights in Tissue Distribution, Metabolism, and Excretion of [3H]-Labeled Antibody Maytansinoid Conjugates in Female Tumor-Bearing Nude Rats.
    Walles M; Rudolph B; Wolf T; Bourgailh J; Suetterlin M; Moenius T; Peraus G; Heudi O; Elbast W; Lanshoeft C; Bilic S
    Drug Metab Dispos; 2016 Jul; 44(7):897-910. PubMed ID: 27122302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of small molecule antibody-drug conjugate catabolites in rat liver and tumor tissue by liquid extraction surface analysis micro-capillary liquid chromatography/tandem mass spectrometry.
    Lanshoeft C; Stutz G; Elbast W; Wolf T; Walles M; Stoeckli M; Picard F; Kretz O
    Rapid Commun Mass Spectrom; 2016 Apr; 30(7):823-32. PubMed ID: 26969923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanistic pharmacokinetic/pharmacodynamic modeling of in vivo tumor uptake, catabolism, and tumor response of trastuzumab maytansinoid conjugates.
    Wada R; Erickson HK; Lewis Phillips GD; Provenzano CA; Leipold DD; Mai E; Johnson H; Tibbitts J
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):969-80. PubMed ID: 25186956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Clinical Disposition and Metabolism of DM1, a Component of Trastuzumab Emtansine (T-DM1), in Sprague Dawley Rats.
    Shen BQ; Bumbaca D; Yue Q; Saad O; Tibbitts J; Khojasteh SC; Girish S
    Drug Metab Lett; 2015; 9(2):119-31. PubMed ID: 26031461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Understanding How the Stability of the Thiol-Maleimide Linkage Impacts the Pharmacokinetics of Lysine-Linked Antibody-Maytansinoid Conjugates.
    Ponte JF; Sun X; Yoder NC; Fishkin N; Laleau R; Coccia J; Lanieri L; Bogalhas M; Wang L; Wilhelm S; Widdison W; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2016 Jul; 27(7):1588-98. PubMed ID: 27174129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.
    Bender B; Leipold DD; Xu K; Shen BQ; Tibbitts J; Friberg LE
    AAPS J; 2014 Sep; 16(5):994-1008. PubMed ID: 24917179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and biodistribution of the antitumor immunoconjugate, cantuzumab mertansine (huC242-DM1), and its two components in mice.
    Xie H; Audette C; Hoffee M; Lambert JM; Blättler WA
    J Pharmacol Exp Ther; 2004 Mar; 308(3):1073-82. PubMed ID: 14634038
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Catabolic fate and pharmacokinetic characterization of trastuzumab emtansine (T-DM1): an emphasis on preclinical and clinical catabolism.
    Shen BQ; Bumbaca D; Saad O; Yue Q; Pastuskovas CV; Khojasteh SC; Tibbitts J; Kaur S; Wang B; Chu YW; LoRusso PM; Girish S
    Curr Drug Metab; 2012 Sep; 13(7):901-10. PubMed ID: 22475269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibody Format and Drug Release Rate Determine the Therapeutic Activity of Noninternalizing Antibody-Drug Conjugates.
    Gébleux R; Wulhfard S; Casi G; Neri D
    Mol Cancer Ther; 2015 Nov; 14(11):2606-12. PubMed ID: 26294742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro characterization of the drug-drug interaction potential of catabolites of antibody-maytansinoid conjugates.
    Davis JA; Rock DA; Wienkers LC; Pearson JT
    Drug Metab Dispos; 2012 Oct; 40(10):1927-34. PubMed ID: 22752008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical Evaluation of
    Hartimath SV; Alizadeh E; Solomon VR; Chekol R; Bernhard W; Hill W; Parada AC; Barreto K; Geyer CR; Fonge H
    J Nucl Med; 2019 Aug; 60(8):1103-1110. PubMed ID: 30655327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitive ELISA Method for the Measurement of Catabolites of Antibody-Drug Conjugates (ADCs) in Target Cancer Cells.
    Salomon PL; Singh R
    Mol Pharm; 2015 Jun; 12(6):1752-61. PubMed ID: 25738394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineered thio-trastuzumab-DM1 conjugate with an improved therapeutic index to target human epidermal growth factor receptor 2-positive breast cancer.
    Junutula JR; Flagella KM; Graham RA; Parsons KL; Ha E; Raab H; Bhakta S; Nguyen T; Dugger DL; Li G; Mai E; Lewis Phillips GD; Hiraragi H; Fuji RN; Tibbitts J; Vandlen R; Spencer SD; Scheller RH; Polakis P; Sliwkowski MX
    Clin Cancer Res; 2010 Oct; 16(19):4769-78. PubMed ID: 20805300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates.
    Erickson HK; Widdison WC; Mayo MF; Whiteman K; Audette C; Wilhelm SD; Singh R
    Bioconjug Chem; 2010 Jan; 21(1):84-92. PubMed ID: 19891424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detection and Characterization of In Vitro Payload-Containing Catabolites of Noncleavable Antibody-Drug Conjugates by High-Resolution Mass Spectrometry and Multiple Data Mining Tools.
    Cai T; Shi L; Guo H; Li R; Cao W; Shen L; Zhu M; Tao Y
    Drug Metab Dispos; 2023 May; 51(5):591-598. PubMed ID: 36707253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates.
    Ait-Oudhia S; Zhang W; Mager DE
    AAPS J; 2017 Sep; 19(5):1436-1448. PubMed ID: 28646408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Affibody-derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over-expressing tumors.
    Altai M; Liu H; Ding H; Mitran B; Edqvist PH; Tolmachev V; Orlova A; Gräslund T
    J Control Release; 2018 Oct; 288():84-95. PubMed ID: 30172673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical modeling of the drug load distribution on trastuzumab emtansine (Kadcyla), a lysine-linked antibody drug conjugate.
    Kim MT; Chen Y; Marhoul J; Jacobson F
    Bioconjug Chem; 2014 Jul; 25(7):1223-32. PubMed ID: 24873191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1).
    Singh AP; Maass KF; Betts AM; Wittrup KD; Kulkarni C; King LE; Khot A; Shah DK
    AAPS J; 2016 Jul; 18(4):861-75. PubMed ID: 27029797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.